Newsfiscal.ai
Agenus Reports Positive Phase 2 Results for BOT+BAL in NEOASIS Study at ESMO 2026
· Published
Article summary
Agenus announced that 72% of patients with locally advanced dMMR colon cancer achieved a pathological complete response following six weeks of neoadjuvant treatment with botensilimab and balstilimab.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…